Liberum cuts target price for Oxford Biomedica, saying it still lacks sufficient scale

by | Nov 28, 2022

Analysts at Liberum cut their target price for shares Oxford Biomedica arguing that the company’s pan-vector offering had yet to reach sufficient scale in order to deliver sustainable profitability.
For that to occur, continued contract wins would be key, they added.

They also adjusted their valuation in response to markets’ attitudes towards risk so that they now only valued known customers.

Nevertheless, the impact of the macroeconomic backdrop on funding for research and development was not as negative as perceived.

The analysts also pushed through 5-15% near-term sales upgrades and now expected the Contract Development and Manufacturing Organisation to breakeven on an earnings before interest, taxes, depreciation and amortisation basis in 2023.

All told, they reiterated their ‘buy’ recommendation on the shares, but cut their target price from 1,390.0p to 1,010.0p.

“In our view, this is a conservative base for attractive investor returns.”

Related articles

RBC Capital cuts Rentokil price target

RBC Capital cuts Rentokil price target

(Sharecast News) - RBC Capital Markets cut its price target on Rentokil Initial on Wednesday to 575p from 610p as it downgraded forecasts for forex and a greater back-end loading of TMX synergies, but said it believes the long-term story remains intact. The bank said...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x